Low dose alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia

Leukemia and Lymphoma

Volumn 53, Issue 3, 2012, Pages 424-429

  Gritti, Giuseppe ^a   Reda, Gianluigi ^b   Maura, Francesco ^b   Piciocchi, Alfonso ^c   Baldini, Luca ^a,b   Molica, Stefano ^d   Neri, Antonino ^a,b   Cortelezzi, Agostino ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^c GIMEMA Data Center   (Italy)

^d PUGLIESE CIACCIO HOSPITAL   (Italy)

Author keywords

Alemtuzumab; Chronic lymphocytic leukemia; Fludarabine; Infections; Refractory

Indexed keywords

ALEMTUZUMAB; FLUDARABINE;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CHYLOTHORAX; CLINICAL ARTICLE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISEASE COURSE; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HEMOLYTIC ANEMIA; HUMAN; INJECTION SITE REACTION; LEUKEMIA REMISSION; LOW DRUG DOSE; LYMPHOCYTE COUNT; MALE; MASTOIDITIS; OVERALL SURVIVAL; PERIANAL ABSCESS; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECTUM HEMORRHAGE; SEPSIS; SKIN ABSCESS; VIRUS REACTIVATION;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HEMATOLOGIC DISEASES; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; SALVAGE THERAPY; VIDARABINE; VIRUS ACTIVATION;

EID: 84857527105     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.623258     Document Type: Article

References (29)

1. R obak T, Dmoszynska A, Solal-Celigny P., et al. Rituximab plus fl udarabine and cyclophosphamide prolongs progression-free survival compared with fl udarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 2010; 28:1756-1765.
2. W ierda W, O'Brien S, Wen S., et al. Chemoimmunotherapy with fl udarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005;23:4070-4078. (Pubitemid 46211312)
3. H allek M, Fischer K, Fingerle-Rowson G., et al. Addition of rituximab to fl udarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010;376:1164-1174.
4. T simberidou AM, Keating MJ. Treatment of fl udarabine-refractory chronic lymphocytic leukemia. Cancer 2009;115:2824-2836.
5. Z enz T, Eichhorst B, Busch R., et al. TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol 2010;28:4473-4479.
6. Z enz T, Habe S, Denzel T., et al. Detailed analysis of p53 pathway defects in fl udarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood 2009; 114:2589-2597.
7. Hale G. Th e CD52 antigen and development of the CAMPATH antibodies. Cytotherapy 2001;3:137-143. (Pubitemid 33039652)
8. G ribben JG, Hallek M. Rediscovering alemtuzumab: current and emerging therapeutic roles. Br J Haematol 2009;144:818-831.
9. Osterborg A, Foa R, Bezares RF., et al. Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia. Leukemia 2009;23:1980-1988.
10. K eating MJ, Flinn I, Jain V., et al. Th erapeutic role of alemtuzumab Campath-1H) in patients who have failed fl udarabine: results of a large international study. Blood 2002;99:3554-3561. (Pubitemid 34534522)
11. Rai KR, Freter CE, Mercier RJ., et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fl udarabine. J Clin Oncol 2002;20:3891-3897.
12. Stilgenbauer S, Zenz T, Winkler D., et al. Subcutaneous alemtuzumab in fl udarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2009;27:3994-4001.
13. Lozanski G, Heerema NA, Flinn IW., et al. Alemtuzumab is an eff ective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 2004;103:3278-3281. (Pubitemid 38525651)
14. Stilgenbauer S, Dohner H. Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. N Engl J Med 2002;347:452-453. (Pubitemid 34851846)
15. N osari A, Montillo M, Morra E. Infectious toxicity using alemtuzumab. Haematologica 2004;89:1415-1419. (Pubitemid 39643505)
16. Nosari A, Tedeschi A, Ricci F., et al. Characteristics and stage of the underlying diseases could determine the risk of opportunistic infections in patients receiving alemtuzumab. Haematologica 2008; 93: e30-e31. (Pubitemid 351397734)
17. Horner MJ RL, Krapcho M, Neyman N, et al editor. SEER Cancer Statistics Review, 1975-2006. National Cancer Institute, Bethesda (MD), available on line at http://seer.cancer.gov/csr/1975-2006/; 2009.
18. Cortelezzi A, Pasquini MC, Gardellini A., et al. Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study. Leukemia 2009;23:2027-2033.
19. C ortelezzi A, Pasquini MC, Sarina B., et al. A pilot study of low-dose subcutaneous alemtuzumab therapy for patients with hemotherapyrefractory chronic lymphocytic leukemia. Haematologica 2005;90: 410-412. (Pubitemid 40388996)
20. C heson BD, Bennett JM, Grever M., et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87:4990-4997. (Pubitemid 26189840)
21. Laurenti L, Piccioni P, Tarnani M., et al. Low-dose intravenous alemtuzumab therapy in pretreated patients aff ected by chronic lymphocytic leukemia. A single center experience. Haematologica 2005;90:1143-1145. (Pubitemid 41323520)
22. Bezares RF, Stemelin G, Diaz A., et al. Multicenter study of subcutaneous alemtuzumab administered at reduced dose in patients with fl udarabine-relapsed/refractory chronic lymphocytic leukemia: fi nal analysis. Leuk Lymphoma 2011;52:1936-1941.
23. Hillmen P, Skotnicki AB, Robak T., et al. Alemtuzumab compared with chlorambucil as fi rst-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007;25:5616-5623.
24. Hale G, Rebello P, Brettman LR., et al. Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. Blood 2004;104:948-955. (Pubitemid 39043667)
25. M orris EC, Rebello P, Th omson KJ., et al. Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications. Blood 2003;102:404-406. (Pubitemid 36759683)
26. Mould DR, Baumann A, Kuhlmann J., et al. Population pharmacokinetics- pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment response. Br J Clin Pharmacol 2007;64:278-291. (Pubitemid 47283867)
27. Hallek M, Pfl ug N. State of the art treatment of chronic lymphocytic leukaemia. Blood Rev 2011;25:1-9.
28. Elter T, Borchmann P, Schulz H., et al. Fludarabine in combination with alemtuzumab is eff ective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. J Clin Oncol 2005;23:7024-7031.
29. K ennedy B, Rawstron A, Carter C., et al. Campath-1H and fl udarabine in combination are highly active in refractory chronic lymphocytic leukemia. Blood 2002;99:2245-2247. (Pubitemid 34525514)